Sanofi (NASDAQ:SNY) Shares Purchased by Code Waechter LLC

Code Waechter LLC raised its stake in Sanofi (NASDAQ:SNY - Free Report) by 77.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 11,905 shares of the company's stock after purchasing an additional 5,212 shares during the period. Code Waechter LLC's holdings in Sanofi were worth $660,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD raised its position in Sanofi by 88.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 10,843,682 shares of the company's stock valued at $522,991,000 after purchasing an additional 5,091,304 shares during the last quarter. Boston Partners raised its position in Sanofi by 86.4% in the 4th quarter. Boston Partners now owns 5,396,531 shares of the company's stock valued at $260,607,000 after purchasing an additional 2,501,073 shares during the last quarter. Magnetar Financial LLC raised its position in Sanofi by 104.3% in the 4th quarter. Magnetar Financial LLC now owns 3,340,317 shares of the company's stock valued at $161,103,000 after purchasing an additional 1,705,148 shares during the last quarter. Point72 Asset Management L.P. raised its position in Sanofi by 969.6% in the 4th quarter. Point72 Asset Management L.P. now owns 950,649 shares of the company's stock valued at $45,850,000 after purchasing an additional 861,770 shares during the last quarter. Finally, Regal Partners Ltd purchased a new position in Sanofi during the 4th quarter worth $35,034,000. 14.04% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Price Performance

NASDAQ:SNY traded down $0.73 during mid-day trading on Friday, hitting $48.61. 1,207,445 shares of the company's stock traded hands, compared to its average volume of 2,330,352. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.69 and a current ratio of 1.37. The firm's 50 day simple moving average is $50.05 and its 200 day simple moving average is $52.11. Sanofi has a 1 year low of $45.80 and a 1 year high of $60.12. The company has a market cap of $119.21 billion, a PE ratio of 17.36, a price-to-earnings-growth ratio of 1.11 and a beta of 0.48.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings results on Thursday, April 24th. The company reported $0.94 EPS for the quarter, topping analysts' consensus estimates of $0.90 by $0.04. The business had revenue of $10.41 billion during the quarter, compared to the consensus estimate of $9.79 billion. Sanofi had a net margin of 14.56% and a return on equity of 17.15%. The company's quarterly revenue was down 11.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.78 earnings per share. Sell-side analysts expect that Sanofi will post 4.36 EPS for the current year.

Sanofi Increases Dividend

The business also recently announced an annual dividend, which was paid on Thursday, June 12th. Investors of record on Friday, May 9th were given a $2.0369 dividend. The ex-dividend date was Friday, May 9th. This is a boost from Sanofi's previous annual dividend of $1.48. This represents a dividend yield of 3.1%. Sanofi's dividend payout ratio (DPR) is currently 57.14%.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Guggenheim restated a "buy" rating on shares of Sanofi in a research report on Tuesday, June 3rd. Morgan Stanley set a $56.00 price objective on shares of Sanofi in a research report on Monday, June 2nd. Hsbc Global Res upgraded shares of Sanofi to a "strong-buy" rating in a research report on Monday, April 28th. Barclays restated an "overweight" rating on shares of Sanofi in a research report on Wednesday, July 2nd. Finally, BNP Paribas assumed coverage on shares of Sanofi in a research report on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price objective for the company. Three investment analysts have rated the stock with a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, Sanofi currently has a consensus rating of "Buy" and an average price target of $61.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.